The overall 5-year relative survival rate for metastatic (stage IV) breast cancer is about 34%, based on the most recent national data from 2016 to 2022. That means roughly one in three people diagnosed with distant-stage breast cancer are alive five years later. But this single number hides enormous variation. Depending on the cancer’s biology, where it has spread, and which treatments are available, some people live months while others live a decade or more.
What the National Numbers Show
The National Cancer Institute’s SEER program, which tracks cancer outcomes across the United States, reports a 33.8% five-year relative survival rate for women with distant-stage breast cancer diagnosed between 2016 and 2022. “Relative survival” compares how long people with cancer live to how long similar people without cancer would be expected to live, so it isolates the effect of the disease itself.
These numbers have been improving steadily. Treatments approved in the last several years take time to show up in population-level statistics because the data always looks backward. Someone diagnosed today has access to therapies that didn’t exist when the people captured in current survival data were treated. That lag matters, and it means real-world outcomes for newly diagnosed patients are likely somewhat better than what the statistics reflect.
Breast Cancer Subtype Changes the Picture Dramatically
Not all metastatic breast cancers behave the same way. The tumor’s hormone receptor (HR) and HER2 status create four major subtypes, and their five-year survival rates for distant disease are strikingly different:
- HR-positive/HER2-positive: 48.7% five-year survival. This is the most favorable subtype at the metastatic stage, partly because it responds to both hormone-blocking therapies and HER2-targeted drugs.
- HR-negative/HER2-positive: 39.5% five-year survival. HER2-targeted treatments have transformed outcomes for this group over the past two decades.
- HR-positive/HER2-negative: 38.1% five-year survival. This is the most common subtype, and newer treatments called CDK4/6 inhibitors have pushed median survival to roughly 55 months (about four and a half years) when used as a first-line approach. A real-world study of over 1,000 patients found a median overall survival of 54.7 months for this group.
- Triple-negative (HR-negative/HER2-negative): 12.8% five-year survival. This subtype has the fewest treatment targets and tends to grow faster. Median survival for advanced triple-negative disease has historically ranged from about 12 to 18 months, though immunotherapy combinations have pushed that to roughly 23 months for patients whose tumors have higher levels of a protein that predicts response to immune-based treatment.
Your oncologist determines subtype through a biopsy, and it’s one of the most important pieces of information in understanding your individual outlook.
Where the Cancer Spreads Matters
Metastatic breast cancer can travel to the bones, lungs, liver, brain, or multiple sites at once. The location and extent of spread significantly affect survival.
Bone-only metastasis carries the best prognosis. A large study of over 19,000 patients with de novo metastatic breast cancer found that those with cancer confined to the bones had a 12% lower risk of death compared to patients with spread to other organs. One study using precision radiation therapy for limited bone metastases reported that 75% of those patients were still alive at 10 years. When cancer has spread to organs like the liver or brain, or to multiple sites simultaneously, survival tends to be shorter. Among women whose cancer had spread beyond the bones, the 10-year survival rate was 17%.
The number of metastatic sites also plays a role. A single spot of spread is generally more manageable than cancer in three or four different organs.
De Novo vs. Recurrent Metastatic Disease
There are two paths to a stage IV diagnosis. Some people are diagnosed with metastatic breast cancer from the start, meaning the cancer has already spread by the time it’s found. This is called “de novo” metastatic disease. Others were previously treated for earlier-stage breast cancer that later returned in a distant part of the body.
Counterintuitively, people diagnosed de novo tend to live longer. One large analysis found a median overall survival of 41 months for de novo metastatic breast cancer compared to 25 months for recurrent metastatic disease, with an overall median of 29 months across both groups. This difference likely reflects the biology of recurrent cancers, which have already survived prior treatment and may be more resistant to therapy.
Long-Term Survival Is Real but Uncommon
While metastatic breast cancer is generally considered treatable but not curable, a meaningful number of people live well beyond five years. The 10-year survival data is less robust, but existing research suggests that somewhere between 10% and 20% of patients with metastatic breast cancer are alive a decade after diagnosis, with higher rates for those whose disease is limited to the bones or a small number of sites.
Some oncologists use the term “exceptional responders” for patients who remain stable on treatment for many years. These cases aren’t fully understood, but they tend to share certain characteristics: hormone receptor-positive disease, limited sites of metastasis, strong response to first-line therapy, and good overall health at diagnosis. Living 10 or even 15 years with metastatic breast cancer is uncommon but documented, and it’s becoming less rare as treatments improve.
What Shapes an Individual Prognosis
Population statistics describe averages across thousands of patients. Your individual outlook depends on a combination of factors that no single number can capture:
- Tumor subtype: The single strongest predictor. HR-positive and HER2-positive cancers have more treatment options and longer expected survival than triple-negative disease.
- Number and location of metastases: Fewer sites and bone-only disease are more favorable.
- Response to treatment: How well the cancer shrinks or stabilizes with initial therapy is a strong signal of how long it can be controlled.
- Overall health: Younger patients and those with fewer other medical conditions tend to tolerate treatment better and live longer.
- Time since original diagnosis: For recurrent disease, a longer gap between the original cancer and the metastatic recurrence often correlates with slower-growing disease.
Treatment sequencing also matters. Metastatic breast cancer is typically managed through a series of therapies, moving to the next option when the current one stops working. For HR-positive/HER2-negative disease, the most common subtype, patients may cycle through multiple lines of hormone-based therapy combined with targeted drugs before moving to chemotherapy. Each line of treatment can provide months to years of disease control. The total time across all treatment lines is what builds up to the survival figures seen in the data.
The pace of new drug approvals in metastatic breast cancer has accelerated considerably. Newer antibody-drug conjugates, which deliver chemotherapy directly to cancer cells, have expanded options for HER2-positive, HER2-low, and even HER2-ultralow patients. These therapies are too new to appear in the five-year survival statistics, which is another reason the published numbers likely underestimate current outcomes.